{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:34:09Z","timestamp":1760783649447},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.juro.2013.02.104","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T20:09:45Z","timestamp":1362082185000},"page":"1173-1180","source":"Crossref","is-referenced-by-count":60,"title":["Selective \u03b2\n            <sub>3<\/sub>\n            -Adrenoceptor Agonists for the Treatment of Overactive Bladder"],"prefix":"10.1097","volume":"190","author":[{"given":"Karl-Erik","family":"Andersson","sequence":"first","affiliation":[{"name":"Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Martin","sequence":"additional","affiliation":[{"name":"Astellas Scientific and Medical Affairs, Northbrook, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Nitti","sequence":"additional","affiliation":[{"name":"New York University Urology Associates, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2013.02.104_bib1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1152\/ajplegacy.1948.153.3.586","article-title":"A study of the adrenotropic receptors","volume":"153","author":"Ahlquist","year":"1948","journal-title":"Am J Physiol"},{"key":"10.1016\/j.juro.2013.02.104_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/214597a0","article-title":"Differentiation of receptor systems activated by sympathomimetic amines","volume":"214","author":"Lands","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.juro.2013.02.104_bib3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1126\/science.2570461","article-title":"Molecular characterization of the human beta 3-adrenergic receptor","volume":"245","author":"Emorine","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.juro.2013.02.104_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.phrs.2009.01.002","article-title":"The beta3-adrenoceptor as a therapeutic target: current perspectives","volume":"59","author":"Ursino","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.juro.2013.02.104_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00210-010-0529-2","article-title":"Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges","volume":"382","author":"Michel","year":"2010","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib6","first-page":"253","article-title":"Pharmacology of lower urinary tract smooth muscles and penile erectile tissues","volume":"45","author":"Andersson","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.juro.2013.02.104_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0773.1977.tb02049.x","article-title":"Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat","volume":"40","author":"Nerg\u00e5rdh","year":"1977","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1016\/j.juro.2013.02.104_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1476-5381.1979.tb07821.x","article-title":"Alpha and beta-Adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man","volume":"65","author":"Larsen","year":"1979","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000281188","article-title":"Terbutaline (Bricanyl) in the treatment of female urge incontinence","volume":"41","author":"Lindholm","year":"1986","journal-title":"Urol Int"},{"key":"10.1016\/j.juro.2013.02.104_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","article-title":"Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence","volume":"19","author":"Andersson","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib11","doi-asserted-by":"crossref","unstructured":"Michel MC and Vrydag W: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, suppl., 2006; 147: S88.","DOI":"10.1038\/sj.bjp.0706619"},{"key":"10.1016\/j.juro.2013.02.104_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00210-008-0274-y","article-title":"Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium","volume":"377","author":"Otsuka","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.ju.0000067621.62736.7c","article-title":"A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders","volume":"170","author":"Nomiya","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-007-0208-0","article-title":"Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors","volume":"377","author":"Frazier","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2011.03.014","article-title":"\u03b2-adrenoceptor agonist effects in experimental models of bladder dysfunction","volume":"131","author":"Michel","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.juro.2013.02.104_bib16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2009.07.044","article-title":"A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature","volume":"56","author":"Roosen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.juro.2009.12.060","article-title":"Bladder afferent signaling: recent findings","volume":"183","author":"Kanai","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1464-410X.2003.04667.x","article-title":"The autonomous bladder: a view of the origin of bladder overactivity and sensory urge","volume":"93","author":"Gillespie","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.02.104_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1113\/jphysiol.1955.sp005327","article-title":"Tension receptors in the stomach and the urinary bladder","volume":"128","author":"Iggo","year":"1955","journal-title":"J Physiol"},{"key":"10.1016\/j.juro.2013.02.104_bib20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/nau.20826","article-title":"Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat","volume":"29","author":"Aizawa","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2013.02.104_bib21","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1464-410X.2006.06564.x","article-title":"The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder","volume":"98","author":"Biers","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.02.104_bib23","doi-asserted-by":"crossref","unstructured":"Andersson KE: Bladder activation: afferent mechanisms. Urology, suppl., 2002; 59: 43.","DOI":"10.1016\/S0090-4295(01)01637-5"},{"key":"10.1016\/j.juro.2013.02.104_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ncpuro0672","article-title":"Mechanisms of disease: involvement of the urothelium in bladder dysfunction","volume":"4","author":"Birder","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1464-410X.2006.06679.x","article-title":"The role of the urothelium in mediating bladder responses to isoprenaline","volume":"99","author":"Murakami","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.02.104_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00441-010-1053-x","article-title":"\u03b2-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder","volume":"342","author":"Limberg","year":"2010","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.juro.2013.02.104_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.104.077768","article-title":"Does cyclic\u00a0AMP mediate rat urinary bladder relaxation by isoproterenol?","volume":"313","author":"Frazier","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.juro.2013.02.104_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrurol.2011.194","article-title":"Role of potassium ion channels in detrusor smooth muscle function and dysfunction","volume":"9","author":"Petkov","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/jpet.107.125757","article-title":"GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog","volume":"323","author":"Hicks","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.juro.2013.02.104_bib30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1476-5381.2010.01005.x","article-title":"Are there functional \u03b23-adrenoceptors in the human heart?","volume":"162","author":"Michel","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11897-011-0064-6","article-title":"Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies","volume":"8","author":"Gauthier","year":"2011","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.juro.2013.02.104_bib32","unstructured":"Astellas Pharma US: Highlights of Prescribing Information. Available at http:\/\/www.us.astellas.com\/docs\/myrbetriq-full-pi.pdf. Accessed February 17, 2013."},{"key":"10.1016\/j.juro.2013.02.104_bib33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1476-5381.2010.00996.x","article-title":"Human\u00a0atrial \u03b2(1L)-adrenoceptor but not \u03b23-adrenoceptor activation increases force and Ca(2+) current at physiological temperature","volume":"162","author":"Christ","year":"2011","journal-title":"Br\u00a0J Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1054-3589(10)59005-7","article-title":"Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives","volume":"59","author":"Dessy","year":"2010","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.juro.2013.02.104_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00210-012-0824-1","article-title":"Pharmacological profile of \u03b2(3)-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome","volume":"386","author":"Igawa","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.juro.2013.02.104_bib37","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.urology.2011.08.080","article-title":"Pharmacological effect of TRK-380, a novel selective human \u03b23-adrenoceptor agonist, on mammalian detrusor strips","volume":"79","author":"Kanie","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.02.104_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.111.043588","article-title":"Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective \u03b2(3)-adrenoceptor agonist, after oral administration to healthy male volunteers","volume":"40","author":"Takusagawa","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.juro.2013.02.104_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3109\/00498254.2012.675095","article-title":"Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective \u03b2(3)-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.juro.2013.02.104_bib40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","article-title":"In\u00a0vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective \u03b23-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.juro.2013.02.104_bib41","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5414\/CP201782","article-title":"Single dose pharmacokinetics and absolute bioavailibility of\u00a0mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder","volume":"50","author":"Eltink","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.juro.2013.02.104_bib42","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","article-title":"Pharmacokinetic properties of mirabegron, a \u03b23-adrenoceptor agonist: results from two phase\u00a0I, randomized, multiple-dose studies in healthy young and elderly men and women","volume":"34","author":"Krauwinkel","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.juro.2013.02.104_bib43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/clpt.2012.181","article-title":"Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study","volume":"92","author":"Malik","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.juro.2013.02.104_bib44","first-page":"239","article-title":"Clinical proof of concept study (BLOSSOM) shows novel Beta3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder","volume":"7","author":"Chapple","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.juro.2013.02.104_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1569-9056(10)60758-0","article-title":"Dose-ranging study of once-daily mirabegron (YM178), a novel selective \u03b23-adrenoceptor agonist, in patients with overactive bladder (OAB)","volume":"9","author":"Chapple","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.juro.2013.02.104_bib46","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy\u00a0and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib48","unstructured":"van Kerrebroeck P, Barkin J, Castro-Diaz D et\u00a0al: Randomised, double-blind, placebo-controlled phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB). Presented at annual meeting of International Continence Society, Beijing, People's Republic of China, October 19, 2012, poster 359. Available at http:\/\/www.icsoffice.org\/Abstracts\/Publish\/134\/000359.pdf. Accessed February 17, 2013."},{"key":"10.1016\/j.juro.2013.02.104_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized Double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.02.104_bib50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713003807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713003807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2013.02.104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:47:21Z","timestamp":1651200441000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2013.02.104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1016\/j.juro.2013.02.104"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2013.02.104","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}